Results 1 to 10 of about 305 (108)

Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab

BMC Pediatrics, 2022
Purpose Real-world data and study data regarding therapy with Emicizumab in pediatric cohorts with haemophilia A is scarce. Especially, data on previously untreated pediatric patients (PUPs) and minimally treated patients (MTPs) are missing.
Hannah Glonnegger, Felicia Andresen, Friedrich Kapp, Stefano Malvestiti, Martin Büchsel, Barbara Zieger   +5 more
doaj   +4 more sources

Emicizumab state‐of‐the‐art update

Haemophilia, 2022
AbstractIntroductionEmicizumab is a bispecific monoclonal antibody developed to address the unmet needs of clotting factor replacement therapy and has become the benchmark for optimal prophylaxis in managing patients with haemophilia A with inhibitors.
Johnny Mahlangu, Alfonso Iorio, Gili Kenet   +2 more
exaly   +4 more sources

Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study

Research and Practice in Thrombosis and Haemostasis, 2022
Background Emicizumab is a new treatment option for people with hemophilia A. Emicizumab was approved with a body‐weight‐based dosage regimen, without laboratory monitoring requirements.
Anouk A M T Donners, Kim C M Van Der Elst   +1 more
exaly   +2 more sources

Emicizumab-induced photosensitivity

TH Open, 2022
Emicizumab constitutes a novel and effective prophylaxis for hemophilia A patients with and without inhibitors. In this case report, we describe an emicizumab-induced photosensitivity that forced permanent sun-exposure suppression.
Pedro Asensi Cantó, Mercedes Rodríguez Serna, Pilar Lloret Madrid, Jürgen Solís Ruiz, Ana Rosa Cid Haro, Santiago Bonanad Boix, Saturnino Haya Guaita   +6 more
doaj   +3 more sources

No correlation between thrombin generation and emicizumab levels: implications for monitoring emicizumab therapy

Research and Practice in Thrombosis and Haemostasis
Background: Emicizumab, a bispecific antibody that mimics factor (F)VIII, has significantly improved hemophilia A management. Although emicizumab levels can be measured, tools for estimating the hemostatic efficacy of emicizumab are lacking.
Konrad van der Zwet, Mark Roest, Dana Huskens, Roger E.G. Schutgens, Lize F.D. van Vulpen, Kathelijn Fischer, Rolf T. Urbanus   +6 more
doaj   +3 more sources

A SIMULATION STUDY TO PROVIDE GUIDANCE FOR INDIVIDUALS TRANSITIONING FROM EMICIZUMAB TO VALOCTOCOGENE ROXAPARVOVEC

Hematology, Transfusion and Cell Therapy, 2023
Aim: Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) is a gene therapy evaluated in the phase 3 GENEr8-1 trial that provides endogenous factor VIII (FVIII) production to prevent bleeding in people with severe hemophilia A and represents an alternative to ...
W Kuwabara, D Osmond, J Henshaw, S Agarwal, V Newman, C Hermans, W Miesbach, S Pipe, RS Jr, F Peyvandi   +9 more
doaj   +1 more source

Differences in venous clot structures between hemophilic mice treated with emicizumab versus factor VIII or factor VIIIFc

Haematologica, 2023
Recombinant factor VIII (rFVIII), rFVIIIFc and emicizumab are established treatment options in the management of hemophilia A. Each has its unique mode of action, which can influence thrombin generation kinetics and therefore also the kinetics of ...
Thibaud Sefiane, Hortense Maynadié, Carmen Escurola Ettingshausen, Vincent Muczynski, Xavier Heiligenstein, Julien Dumont, Olivier D. Christophe, Cécile V. Denis, Caterina Casari, Peter J. Lenting   +9 more
doaj   +1 more source

The effect of emicizumab and bypassing agents in patients with hemophilia – An in vitro study

Research and Practice in Thrombosis and Haemostasis, 2021
Background Emicizumab is a nonfactor replacement therapy for hemophilia A (HA) and is a bispecific monoclonal antibody mimicking factor VIII by binding both factors IXa and X.
Nina Haagenrud Schultz, Heidi Glosli, Stine Bjørnsen, Pål Andre Holme   +3 more
doaj   +1 more source

Influence of emicizumab on protein C-mediated clotting regulation

Bleeding, Thrombosis and Vascular Biology, 2023
Emicizumab, a FVIII-mimetic bispecific antibody, is insensitive to degradation by activated protein C (APC) and may thus induce a procoagulant state. We investigated the effect of emicizumab on protein C-mediated inhibition of coagulation under in vitro
Federica Mancazzo, Antonia Vitulli, Lavinia Dirienzo, Concetta T. Ammollo, Fabrizio Semeraro, Mario Colucci   +5 more
doaj   +1 more source

Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single‐center report

Research and Practice in Thrombosis and Haemostasis, 2021
Background Emicizumab, a bispecific antibody factor VIII mimetic, is approved for prophylaxis in hemophilia, and has different risks and side effects compared to factor VIII products.
Beth Boulden Warren, Adrian Chan, Marilyn Manco‐Johnson, Brian R. Branchford, Tyler W. Buckner, Genevieve Moyer, Elizabeth Gibson, Dianne Thornhill, Michael Wang, Christopher J Ng   +9 more
doaj   +1 more source